A MULTICENTER LONGITUDINAL-STUDY COMPARING THE SENSITIVITY OF MONTHLYMRI AFTER STANDARD AND TRIPLE DOSE GADOLINIUM-DTPA FOR MONITORING DISEASE-ACTIVITY IN MULTIPLE-SCLEROSIS - IMPLICATIONS FOR PHASE-II CLINICAL-TRIALS
M. Filippi et al., A MULTICENTER LONGITUDINAL-STUDY COMPARING THE SENSITIVITY OF MONTHLYMRI AFTER STANDARD AND TRIPLE DOSE GADOLINIUM-DTPA FOR MONITORING DISEASE-ACTIVITY IN MULTIPLE-SCLEROSIS - IMPLICATIONS FOR PHASE-II CLINICAL-TRIALS, Brain (Print), 121, 1998, pp. 2011-2020
In this study we assessed the safety, efficacy and cost-effectiveness
of the use of triple dose gadolinium-DTPA (Gd) in serial monthly brain
MRI of patients with multiple sclerosis, such as could be selected fo
r clinical trials. The number of enhancing lesions, the number of new
enhancing lesions and the number of active scans were used to evaluate
the sensitivity of the contrast-enhanced MRI to disease activity. The
dose of Gd, and the effect of introducing a delay between the contras
t injection and the scan were both appraised. Every 4 weeks for 3 mont
hs, and in two separate sessions, scans were obtained from 40 patients
with relapsing-remitting or secondary progressive multiple sclerosis,
5 min (early) and 20 min (delayed) after a standard dose (0.1 mmol/kg
) or triple dose (0.3 mmol/kg) Gd injection, There were 435 enhancing
lesions (242 of which were new) on the early standard dose scans, 479
(263 new) on the delayed standard dose, 772 (365 new) on the early tri
ple dose and 827 (404 ne cr) on the delayed triple dose. There were 10
9 scans revealing active disease on the early standard dose scans, 112
on the delayed standard dose, 119 on the early triple dose and 120 on
the delayed triple dose, Statistical simulations indicated that the s
ample sizes needed for both cross-over and parallel-group trials with
similar powers are lower if serial monthly triple dose MRI is used. No
side-effects were reported and no significant changes in blood test p
arameters were found throughout the study. This study shows that the s
erial use of triple dose Gd is safe, and that it increases the sensiti
vity of serial monthly enhanced MRI in detecting multiple sclerosis ac
tivity significantly. Its use should enable preliminary trials of expe
rimental therapies for multiple sclerosis to be conducted in small pat
ient populations, over a short period of time.